We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
From classical Langerhans cell histiocytosis to Erdheim- -Chester disease: different sides of the same coin?
- Authors
Grześk, Elżbieta; Dąbrowska, Anna; Kołtan, Sylwia; Wysocki, Mariusz; Czyżewski, Krzysztof; Styczyński, Jan
- Abstract
Introduction: We analysed the clinical course of classical histiocytosis (LCH) in children, and the clinical differences, diagnostic difficulties and different therapeutic strategy in a child with a rare variant of LCH in the form of Erdheim- Chester disease (ECD). Material and methods: We conducted a retrospective single-center analysis of the clinical course of classic LCH in 54 children who were diagnosed with the disease over the last 40 years, and the differences shown in a patient with diagnosed ECD. The clinical response was assessed according to the LCH programs valid at the time for the classic form of LCH and in the child with ECD. Results: The multi-system form of LCH was diagnosed more often than the single-system form. The skull bones were the most common localization of LCH in both forms of the disease. Recurrence of the disease occurred in about 5% of patients, and death in one (1.9%) patient. The course of the child with ECD was more turbulent, with rapid progression, the involvement of critical organs, and no response to standard chemotherapy according to the LCH 2009 protocol. After a molecular diagnosis was specified, therapy with vemurafenib, a BRAF-V600E kinase inhibitor, followed by allogeneic hematopoietic stem cells transplantation (allo-HSCT) was applied. The basic disease has been in remission for the last 12 months. Conclusions: The lack of an expected response to LCH therapy should indicate the possibility of rare forms of histiocytic hyperplasia. Molecular tests are an important element in the diagnosis of histiocytosis, and allow the precise selection of the most appropriate, targeted therapy. BRAF-V600E kinase inhibitors are highly safe and effective in the treatment of LCH and ECD with a confirmed BRAF-V600E mutation, although allo-HSCT should be considered in selected cases.
- Subjects
LANGERHANS-cell histiocytosis; ERDHEIM-Chester disease; GENETIC mutation; HYPERPLASIA; PEDIATRICS
- Publication
Acta Haematologica Polonica, 2021, Vol 52, Issue 6, p571
- ISSN
0001-5814
- Publication type
Article
- DOI
10.5603/AHP.2021.0089